XML 40 R23.htm IDEA: XBRL DOCUMENT
v3.25.1

Warrants | 3 Months Ended
--- | ---
Mar. 31, 2025
Warrants |
Warrants | Note 15 – Warrants In October 2020, the Company issued warrants to purchase 399,998 shares of common stock in connection with a convertible note financing with an initial fair value of $267,999. The warrants have a five-year 5 term and an exercise price of $1.50. In January 2021, the Company issued warrants to purchase 675,000 shares of common stock in connection with a convertible note financing with an initial fair value of $2,870,666. The warrants have a five-year 5 term and an exercise price of $1.50. In May 2021, the Company issued warrants to purchase 200,000 shares of common stock to the placement agent of its common stock offering. The warrants have a five-year 5 term and an exercise price of $5.00. In July 2021, the Company issued warrants to purchase 533,333 shares of common stock to the placement agent of its common stock offering. The warrants have a five-year 5 term and an exercise price of $5.625. In December 2023, the Company issued warrants to purchase 736,000 shares of common stock to the placement agent of its common stock offering. The warrants have a five-year 5 term and an exercise price of $0.625. In September 2024, the Company issued warrants to purchase 750,000 shares of common stock to Lind, as further described in Note 12. The warrants have a five-year 5 term and an exercise price of $6.50. No value was assigned to the warrants under the Monte Carlo simulation model due to the fair market value of the convertible note payable being in excess of the proceeds received. In November 2024, the Company issued warrants to purchase 326,000 shares of common stock to Lind, as further described in Note 12. The warrants have a five-year 5 term and an exercise price of $9.20. No value was assigned to the warrants under the Monte Carlo simulation model due to the fair market value of the convertible note payable being in excess of the proceeds received. In February 2025, the Company issued warrants to purchase 1,000,000 shares of common stock to Lind, as further described in Note 12. The warrants have a five-year 5 term and an exercise price of $15.00 which was amended to $7.52 on the First Amendment to the agreement on April 9, 2025. See Note 19 for further information. No value was assigned to the warrants under the Monte Carlo simulation model due to the fair market value of the convertible note payable being in excess of the proceeds received. The following table summarizes the changes in warrants outstanding since December 31, 2024. Schedule of Changes in Warrants Outstanding
|  | Number of Shares |  |  | Weighted-average Exercise Price per Share |  |  | Weighted-average Remaining Contractual Term (in years) |  |  | Aggregate Intrinsic Value |
Outstanding at December 31, 2024 |  |  | 914,056 |  |  | $ | 4.76 |  |  |  | 2.40 |  |  | $ | 7,397,542 |
Granted |  |  | 1,000,000 |  |  |  | 7.62 |  |  |  | 4.87 |  |  |  | — |
Exercised |  |  | (82,623 | ) |  |  | 5.45 |  |  |  | — |  |  |  | — |
Outstanding at March 31, 2025 |  |  | 1,831,433 |  |  | $ | 6.29 |  |  |  | 3.68 |  |  | $ | 2,073,198 |

X
- References No definition available. + Details
Name: | RCAT_DisclosureWarrantsAbstract
Namespace Prefix: | RCAT_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of warrant. + References No definition available. + Details
Name: | RCAT_WarrantsDisclosureTextBlock
Namespace Prefix: | RCAT_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration